The Cre/loxP system is a powerful tool for generating conditional genomic recombination and is often used to examine the mechanistic role of specific genes in tumorigenesis. However, Cre toxicity due to its non-specific endonuclease activity has been a concern. Here, we report that tamoxifen-mediated Cre activation in vivo induced the regression of primary lymphomas in p532/2 mice. Our findings illustrate that Cre activation alone can induce the regression of established tumors.
Introduction
The Cre/loxP system has been widely used to induce tissue-and developmental stage-specific genomic recombination [1, 2] . Cre/ loxP is a particularly tractable strategy to examine the role of gene activation or inactivation in the initiation and maintenance of tumorigenesis. However, Cre activation can also induce nonspecific genomic recombination. In some cases, Cre activation has been shown to induce significant cellular toxicity associated with marked cell death in cell culture [3] [4] [5] . This toxicity is not seen in Cre mutants that do not have endonuclease activities [3] .
Similarly, Cre activation in vivo in mouse models can induce toxicity in normal cellular lineages. For example, in mouse lines with Cre expressed in neuronal progenitors, defects have been observed in brain development [6] . Myocardial-specific Cre activation with tamoxifen in the aMHC-MERCreMER mice induces cardiac fibrosis and heart failure [7, 8] . Furthermore, systemic Cre activation with tamoxifen in the Rosa26-CreER T2 mice results in thymic atrophy and severe hematological toxicity [9] .
The Cre/loxP system has been used to interrogate the role of specific genes in tumorigenesis [2] . Although most studies have presumed that Cre does not have effects on tumorigenesis, one report described that Cre expression blocked tumor formation in a mouse model of lymphoma transplantation [10] . Here we report that Cre activation resulted in the regression of primary lymphoma induced by p53 deficiency. Our results have implications for the use of the Cre/loxP system for tumorigenesis studies.
Methods

Lymphoma model
All animal work was approved by the Stanford IACUC committee (protocol number 14045) and follows AAALAC guidelines. The p53 deficient mice (p532/2) were used as the spontaneous lymphoma model. The p532/2 mice were maintained in the FVB/N background and the majority of them developed malignant lymphoma within 6 months of age [11] . The UBC-Cre-ER T2 mice carrying the transgenic Cre-ER T2 controlled by the Ubiquitin C (UBC) promoter were maintained in the 129S6 background [12] . The p532/2 mice were crossed with the UBCCre-ER T2 mice to derive the UBC-Cre-ER T2 ; p532/2 mice.
Conditional Cre activation
For in vivo activation of Cre, the mice were gavaged with tamoxifen (200 mg/kg, once daily, with one day off after 4 consecutive doses) for 9 days. For in vitro activation of Cre, the p532/2 lymphoma cell lines carrying either MSCV empty vector or MSCV-Cre-ER T2 were treated with 1 micromolar of 4-hydroxytamoxifen (Sigma, H7904) for 48 hours.
Flow cytometric analysis of apoptosis
For detection of apoptosis, the lymphoma cells were stained with Annexin V and 7-AAD and analyzed with a FACSCalibur (BD Biosciences). The apoptotic cell populations were visualized with FlowJo (Treestar).
Immunohistochemical analysis of apoptosis
For detection of apoptosis in vivo, the thymic lymphomas from mice treated with tamoxifen were fixed, paraffin-embedded and sectioned. Tissue slides were stained with a cleaved-Caspase 3 antibody (Cell Signaling #9661) following manufacturer's instructions. The slides were developed with DAB (Vector Laboratories) and also counterstained with hematoxylin.
Results and Discussion
The p53 deficient mice (p532/2) were used as the spontaneous lymphoma model. As previously reported, the p532/2 mice developed malignant lymphoma within 6 months of age [11] . The UBC-Cre-ER T2 was introduced into the p532/2 background by crossing. Upon Cre activation with tamoxifen treatment, the temporal regression of UBC-Cre-ER T2 ; p532/2 lymphoma was observed in multiple independent tumors as measured by MRI imaging (Figure 1 ). Tumor volume quantification using MRI image stacks showed that the size of the UBC-Cre-ER T2 ; p532/2 lymphoma was reduced to 0%-30% of the pretreatment level ( Figure 2 ). The regression of the tumors was also visually confirmed by postmortem dissection. In contrast, the volume of the p532/2 lymphoma without UBC-Cre-ER T2 transgene increased 4-6 fold despite tamoxifen treatment (Figure 2) .
To investigate the mechanism of lymphoma regression, we tested whether Cre activation could induce apoptosis in a p532/2 lymphoma cell line derived from the mouse model. Cre-ER T2 was overexpressed in the p532/2 lymphoma cell line with the retroviral Murine Stem Cell Virus (MSCV-Cre-ER T2 ). Upon Cre activation in cell culture with one micromolar of 4-hydroxytamoxifen, there was a four-fold increase of apoptotic cells (11% to 42%) as shown by flow cytometric analysis after Annexin V/7-AAD staining. In contrast, the control p532/2 lymphoma cell line carrying an empty MSCV vector did not show significant changes in apoptosis rate (Figure 3) . To further test whether Cre activation could induce apoptosis in vivo, we stained the p532/2 thymic lymphomas using a cleaved-Caspase 3 antibody. Tamoxifen treatment induced a significant increase in cleaved-Caspase 3 staining (1% to 18%) in the p532/2; UBCCre-ER T2 tumors but only moderate changes in the control p532/ 2 tumors (Figure 4) . Hence, Cre activation induced significant cell death which can contribute to the in vivo tumor regression in the p532/2 mouse model.
Our results are the first to demonstrate that Cre activation alone can induce the regression of established primary tumors in vivo. We found that Cre activation can induce marked apoptosis in p532/2 lymphoma. Our results are consistent with prior reports that Cre activation can result in toxicity in normal tissues [6] [7] [8] [9] . The most likely explanation for our finding is that Cre activation induces genomic rearrangement associated with the cryptic loxP sites within the mouse genome [9] . We recognize that the effects of Cre are likely dose-and duration-dependent.
Our findings reinforced the previous notion that, for studies with the Cre/loxP system, an experimental control using mice with Cre expression but without the loxP sites should always be included for the possibility that Cre activation can markedly perturb the initiation and progression of tumorigenesis and even induce the regression of established tumors [10] .
